JP2024516392A5 - - Google Patents

Info

Publication number
JP2024516392A5
JP2024516392A5 JP2023565419A JP2023565419A JP2024516392A5 JP 2024516392 A5 JP2024516392 A5 JP 2024516392A5 JP 2023565419 A JP2023565419 A JP 2023565419A JP 2023565419 A JP2023565419 A JP 2023565419A JP 2024516392 A5 JP2024516392 A5 JP 2024516392A5
Authority
JP
Japan
Prior art keywords
igg
human
molecule
oligomer
region
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
JP2023565419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516392A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/026505 external-priority patent/WO2022232246A1/en
Publication of JP2024516392A publication Critical patent/JP2024516392A/ja
Publication of JP2024516392A5 publication Critical patent/JP2024516392A5/ja
Withdrawn legal-status Critical Current

Links

JP2023565419A 2021-04-28 2022-04-27 抗体定常領域バリアントを有する結合分子の多量体化 Withdrawn JP2024516392A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163180969P 2021-04-28 2021-04-28
US63/180,969 2021-04-28
PCT/US2022/026505 WO2022232246A1 (en) 2021-04-28 2022-04-27 Multimerization of binding molecules having an antibody constant region variant

Publications (2)

Publication Number Publication Date
JP2024516392A JP2024516392A (ja) 2024-04-15
JP2024516392A5 true JP2024516392A5 (https=) 2025-05-02

Family

ID=83847261

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023565419A Withdrawn JP2024516392A (ja) 2021-04-28 2022-04-27 抗体定常領域バリアントを有する結合分子の多量体化

Country Status (7)

Country Link
US (1) US20240209116A1 (https=)
EP (1) EP4330277A4 (https=)
JP (1) JP2024516392A (https=)
CN (2) CN117255800A (https=)
AU (1) AU2022266780A1 (https=)
CA (1) CA3216755A1 (https=)
WO (1) WO2022232246A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4206226A4 (en) * 2020-08-31 2024-10-16 Medytox Inc. Anti-vegf hexameric antibody and composition comprising same

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6509724B2 (ja) * 2012-04-20 2019-05-08 アプティーボ リサーチ アンド デベロップメント エルエルシー Ｃｄ３結合ポリペプチド
CN104736174B (zh) * 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
JP2015524821A (ja) * 2012-08-02 2015-08-27 ジェイエヌ バイオサイエンシーズ エルエルシー システイン変異及びμ尾部を介して多量体化した抗体又は融合タンパク質
JP6685924B2 (ja) * 2014-04-11 2020-04-22 メディミューン，エルエルシー システイン操作抗体を含むコンジュゲート化合物
KR20180002653A (ko) * 2015-04-07 2018-01-08 제넨테크, 인크. 효능작용 활성을 갖는 항원 결합 복합체 및 사용 방법

Similar Documents

Publication Publication Date Title
US9145454B2 (en) Monoclonal antibodies for Ebola and Marburg viruses
JP2021524270A5 (https=)
JP7624185B2 (ja) 新規抗ｐａｄ４抗体
JP2021524275A5 (https=)
JP6587609B2 (ja) 強皮症治療のための抗ｃｃｌ２及び抗ｌｏｘｌ２併用療法
JP7533897B2 (ja) 融合タンパク質およびその使用
EP2780371A1 (en) Anti-adrenomedullin (adm) antibody or anti-adm antibody fragment or anti-adm non-ig scaffold for regulating the fluid balance in a patient having a chronic or acute disease
JP2023530663A5 (https=)
JP2023544143A5 (https=)
JP2023528207A5 (https=)
JP2018529635A5 (https=)
JP2018514193A5 (https=)
TWI734410B (zh) 阻礙血管內皮脂酶之酵素活性的人類化單株抗體
KR102652664B1 (ko) 조절 t 세포 표면 항원의 에피토프 및 이에 특이적으로 결합하는 항체
JPWO2020059847A5 (https=)
JP2023500248A5 (https=)
JP2021181450A (ja) 細胞内抗原に対して向けられた単一ドメイン抗体
JP2021508495A5 (https=)
JP2022548499A (ja) 非オピオイド組成物及び疼痛管理のための治療法
JP2020535811A5 (https=)
JP2024516392A5 (https=)
CN105542003B (zh) 一种针对rsv粘附g蛋白表面抗原的全人源单克隆抗体
TW202328176A (zh) 抗-sars-cov-2抗體組成物及其用途
JP2024530021A5 (https=)
JP2018500879A5 (https=)